Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N.
Otsuka T, et al.
Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5.
Int J Clin Oncol. 2021.
PMID: 33656656
No abstract available.